COR Quote, Financials, Valuation and Earnings

Cardinal Health has a net margin of 0.95% compared to Cencora's net margin of 0.92%. Cencora's return on equity of 183.42% beat Cardinal Health's return on equity of --.

Cencora has a consensus price target of $317.09, signalling upside risk potential of 9.26%. On the other hand Cardinal Health has an analysts' consensus of $155.47 which suggests that it could grow by 0.79%. Given that Cencora has higher upside potential than Cardinal Health, analysts believe Cencora is more attractive than Cardinal Health.

Cencora has a beta of 0.604, which suggesting that the stock is 39.596% less volatile than S&P 500. In comparison Cardinal Health has a beta of 0.662, suggesting its less volatile than the S&P 500 by 33.768%.

Cencora has a quarterly dividend of $0.55 per share corresponding to a yield of 0.74%. Cardinal Health offers a yield of 1.31% to investors and pays a quarterly dividend of $0.51 per share. Cencora pays 27.58% of its earnings as a dividend. Cardinal Health pays out 58.57% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Cencora quarterly revenues are $75.5B, which are larger than Cardinal Health quarterly revenues of $54.9B. Cencora's net income of $717.9M is higher than Cardinal Health's net income of $506M. Notably, Cencora's price-to-earnings ratio is 33.67x while Cardinal Health's PE ratio is 24.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cencora is 0.18x versus 0.17x for Cardinal Health. Usually stocks with elevated PS ratios are considered overvalued.

Standard BioTools has a net margin of 0.95% compared to Cencora's net margin of -63.81%. Cencora's return on equity of 183.42% beat Standard BioTools's return on equity of -26.52%.

Cencora has a consensus price target of $317.09, signalling upside risk potential of 9.26%. On the other hand Standard BioTools has an analysts' consensus of $2.38 which suggests that it could grow by 119.91%. Given that Standard BioTools has higher upside potential than Cencora, analysts believe Standard BioTools is more attractive than Cencora.

Cencora has a beta of 0.604, which suggesting that the stock is 39.596% less volatile than S&P 500. In comparison Standard BioTools has a beta of 1.804, suggesting its more volatile than the S&P 500 by 80.443%.

Cencora has a quarterly dividend of $0.55 per share corresponding to a yield of 0.74%. Standard BioTools offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cencora pays 27.58% of its earnings as a dividend. Standard BioTools pays out -- of its earnings as a dividend. Cencora's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cencora quarterly revenues are $75.5B, which are larger than Standard BioTools quarterly revenues of $40.8M. Cencora's net income of $717.9M is higher than Standard BioTools's net income of -$26M. Notably, Cencora's price-to-earnings ratio is 33.67x while Standard BioTools's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cencora is 0.18x versus 2.38x for Standard BioTools. Usually stocks with elevated PS ratios are considered overvalued.

McKesson has a net margin of 0.95% compared to Cencora's net margin of 1.39%. Cencora's return on equity of 183.42% beat McKesson's return on equity of --.

Cencora has a consensus price target of $317.09, signalling upside risk potential of 9.26%. On the other hand McKesson has an analysts' consensus of $744.58 which suggests that it could grow by 2.82%. Given that Cencora has higher upside potential than McKesson, analysts believe Cencora is more attractive than McKesson.

Cencora has a beta of 0.604, which suggesting that the stock is 39.596% less volatile than S&P 500. In comparison McKesson has a beta of 0.525, suggesting its less volatile than the S&P 500 by 47.469%.

Cencora has a quarterly dividend of $0.55 per share corresponding to a yield of 0.74%. McKesson offers a yield of 0.38% to investors and pays a quarterly dividend of $0.71 per share. Cencora pays 27.58% of its earnings as a dividend. McKesson pays out 10.47% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Cencora quarterly revenues are $75.5B, which are smaller than McKesson quarterly revenues of $90.8B. Cencora's net income of $717.9M is lower than McKesson's net income of $1.3B. Notably, Cencora's price-to-earnings ratio is 33.67x while McKesson's PE ratio is 28.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cencora is 0.18x versus 0.26x for McKesson. Usually stocks with elevated PS ratios are considered overvalued.

Pineapple has a net margin of 0.95% compared to Cencora's net margin of --. Cencora's return on equity of 183.42% beat Pineapple's return on equity of --.

Cencora has a consensus price target of $317.09, signalling upside risk potential of 9.26%. On the other hand Pineapple has an analysts' consensus of -- which suggests that it could fall by --. Given that Cencora has higher upside potential than Pineapple, analysts believe Cencora is more attractive than Pineapple.

Cencora has a beta of 0.604, which suggesting that the stock is 39.596% less volatile than S&P 500. In comparison Pineapple has a beta of 36.643, suggesting its more volatile than the S&P 500 by 3564.318%.

Cencora has a quarterly dividend of $0.55 per share corresponding to a yield of 0.74%. Pineapple offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cencora pays 27.58% of its earnings as a dividend. Pineapple pays out -- of its earnings as a dividend. Cencora's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cencora quarterly revenues are $75.5B, which are larger than Pineapple quarterly revenues of --. Cencora's net income of $717.9M is higher than Pineapple's net income of --. Notably, Cencora's price-to-earnings ratio is 33.67x while Pineapple's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cencora is 0.18x versus 32.06x for Pineapple. Usually stocks with elevated PS ratios are considered overvalued.